-

Tempus to Participate in the Piper Sandler 37th Annual Healthcare Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3rd in New York City. Jim Rogers, Chief Financial Officer at Tempus, will participate in a fireside chat at 10:30 AM ET.

The live webcast will be available through the events page of Tempus’ Investor Relations website or by clicking the following link: https://event.webcasts.com/starthere.jsp?ei=1743260&tp_key=c0dedf6883.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Contacts

Tempus Communications
Erin Carron
Erin.carron@tempus.com

Tempus Investor Relations
Elizabeth Krutoholow
investorrelations@tempus.com

Tempus AI, Inc.

NASDAQ:TEM

Release Versions

Contacts

Tempus Communications
Erin Carron
Erin.carron@tempus.com

Tempus Investor Relations
Elizabeth Krutoholow
investorrelations@tempus.com

More News From Tempus AI, Inc.

Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the publication of a new study in JCO Precision Oncology highlighting how advanced features of comprehensive genomic profiling (CGP) expand treatment options for cancer patients in community oncology settings. The study, conducted in collaboration with The Oncology Institute (TOI), reveals that features such as tumor-normal matched sequencing, R...

Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Merck, known as MSD outside of the United States and Canada, today announced an expanded, multi-year collaboration aimed at accelerating the discovery and development of precision medicine biomarkers and supporting Merck’s oncology and potentially broader therapeutic portfolios. “This collaboration builds on our existing relationship and reflects our shared...

Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Morgan Stanley Technology, Media, and Telecom Conference on Tuesday, March 3 in San Francisco. Eric Lefkofsky, Tempus Founder and CEO, will participate in a fireside chat at 9:15 AM PST. The live webcast may be accessed directly using the following link: https://event.webcasts.com/starthere.jsp?ei=1753938&tp_k...
Back to Newsroom